Therapeutic efficiency and safety assessment of intradermal platelet rich plasma combined with oral tranexamic acid in patients with facial melasma

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230317003

Enrollment

Registered

2023-03-17

Start date

2023-03-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial melasma Melasma

Interventions

Intradermal platelet rich plasma combined with oral tranexamic acid,Intradermal platelet rich plasma

Experimental Other,Active Comparator Biological/Vaccine

PRP and TXA,PRP

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years 2. Diagnosed with facial melasma by dermatologists

Exclusion criteria

Exclusion criteria: 1. Not willing to participate to the study 2. Allergic to lidocaine, prilocaine, tranexamic acid, chlorhexidine or isopropyl alcohol 3. Allergic to blood components 4. Currently treated with other modalities of melasma (or within 6 months) 5. Pregnancy or lactation 6. History of hematologic disorders 7. History of neurologic disorders 8. History of cancer 9. Hormonal therapy 10. Smoking/alcohol drinking 11. Abnormal liver function test (alanine aminotransferase > 5 times upper normal limits) 12. Abnormal creatinine (serum creatinine > 3.5 mg/dL) 13. Methemoglobinemia 14. Sepsis

Design outcomes

Primary

Measure	Time frame
modified Melasma Area Severity Index (mMASI) 12 weeks Scores	—

Secondary

Measure	Time frame
Physician's Global Assessment (PGA) 12 weeks Scores,Patient satisfcation 12 weeks Scores,Melasma Quality of Life scale (MELASQOL) 12 weeks Scores	—

Countries

Thailand

Contacts

Public ContactWeeratian Tawanwongsri

Walailak University

weeratian.ta@gmail.com075673082

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026